Valaciclovir versus aciclovir for the treatment of primary genital herpes simplex: a cost analysis.

Abstract

The current guidelines for the treatment of primary herpes simplex in the Genito-urinary department in Sheffield Teaching Hospitals NHS Foundation Trust, recommend valaciclovir as a first-line medication. This is a prodrug of aciclovir, which has been used for many years as a treatment for primary herpes simplex virus. The basis of the recommendation largely relates to valaciclovir being more bioavailable than aciclovir. However, there is no evidence to suggest this has an effect on overall outcome with regard to symptom control and viral shedding. The purpose of the service evaluation was to discover if significant cost savings could be made by changing the prescribing policy to make aciclovir the drug of choice for primary herpes simplex virus. Based on 160 patients receiving valaciclovir (500 mg BD) during April 2013 and March 2014, if they had been treated with aciclovir (400 mg TDS) instead, a saving of £828.80 (66% reduction) could have been made.

• Authors: Melissa Pinder, Alison Wright
• Journal: International journal of STD & AIDS (Int J STD AIDS) Vol. 26 Issue 13 Pg. 971-3 (Nov 2015) ISSN: 1758-1052 [Electronic] England
• PMID: 25505043 (Publication Type: Journal Article)
• Copyright: © The Author(s) 2015.

Chemical References

• Antiviral Agents
• Valine
• Valacyclovir
• Acyclovir

Topics

• Acyclovir (analogs & derivatives, economics, therapeutic use)
• Antiviral Agents (economics, therapeutic use)
• Costs and Cost Analysis (methods)
• Herpes Genitalis (drug therapy, virology)
• Humans
• Male
• Medical Audit
• Recurrence
• Simplexvirus (drug effects, isolation & purification)
• Treatment Outcome
• Valacyclovir
• Valine (analogs & derivatives, economics, therapeutic use)
• Virus Shedding